TRL is an independent subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation (MTPC) whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases.
TRL discontinued its research on small molecules in January 2010 and redirected its focus towards biological agents. The "New TRL" reopened in the spring of 2010 with an emphasis on immunological...
"Inspiring medicine, inspiring company"
Guided by our corporate philosophy of "contributing to the healthier lives of people around the world through the creation of pharmaceuticals", Tanabe Research Laboratories is dedicated to discovering effective biological drugs that will meet future medical needs.
Established in 1990, Tanabe Research Laboratories initially focused on small molecule drug discovery in the field of metabolics and inflammation/immunology. At the beginning of 2010, we restructured the organization and directed our efforts towards biologics instead of small molecule compounds. We have created a new research plan directed towards treating autoimmune diseases, which was initiated in the spring of 2010, and are actively building a new research organization to accomplish these goals.
We continue to share the same sense of values and pride in the way our science contributes to the welfare of patients. We feel confident in our scientific team and look forward to a new and exciting era in Tanabe Research Laboratories' research and its long term success.